In Favor

Large, randomized control trials have shown the efficacy of low-dose aspirin (ldASA) in reducing rates of clinically significant severe preterm pre-eclampsia in high-risk populations. Multiple societies have recommended varying risk-stratifying criteria over the last decade. Unfortunately, current approaches to risk-based administration have failed to improve outcomes in an overall high-risk population in the US. Increasing evidence has shown universal ldASA prescription as a practical approach to bridging known gaps in health care for the highest risk patients. This review addresses the benefits of implementing a universal protocol for the administration of ldASA in pregnancy to reduce maternal morbidity and mortality.